Corp Incyte Net Worth

The estimated Net Worth of Corp Incyte is at least $856 Millón dollars as of 16 June 2020. Corp Incyte owns over 214,000 units of Merus N.V stock worth over $853,400,831 and over the last 8 years Corp sold MRUS stock worth over $2,883,520.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Corp Incyte MRUS stock SEC Form 4 insiders trading

Corp has made over 3 trades of the Merus N.V stock since 2017, according to the Form 4 filled with the SEC. Most recently Corp sold 214,000 units of MRUS stock worth $783,240 on 16 June 2020.

The largest trade Corp's ever made was buying 10,000,000 units of Merus N.V stock on 14 February 2017 worth over $60,000,000. On average, Corp trades about 2,697,750 units every 304 days since 2017. As of 16 June 2020 Corp still owns at least 16,972,968 units of Merus N.V stock.

You can see the complete history of Corp Incyte stock trades at the bottom of the page.

What's Corp Incyte's mailing address?

Corp's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON,, DE, 19803.

Insiders trading at Merus N.V

Over the last 5 years, insiders at Merus N.V have traded over $76,701,272 worth of Merus N.V stock and bought 4,110,523 units worth $71,063,751 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... y Corp Incyte. On average, Merus N.V executives and independent directors trade stock every 18 days with the average trade being worth of $4,323,728. The most recent stock trade was executed by Harry Shuman on 20 August 2024, trading 5,000 units of MRUS stock currently worth $251,400.

What does Merus N.V do?

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Complete history of Corp Incyte stock trades at Agenus Inc y Merus N.V

Merus N.V executives and stock owners

Merus N.V executives and other stock owners filed with the SEC include:

• Hui Liu,
  Chief Business Officer and Head of Merus U.S.
• Dr. Sven Ante Lundberg M.D.,
  CEO, Pres, Principal Financial Officer & Exec. Director
• Peter B. Silverman J.D.,
  Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal
• Hui Liu,
  Chief Bus. Officer, Exec. VP & Head of Merus U.S.
• Alexander Bakker,
  Chief Development Officer
• Peter Silverman,
  General Counsel, Chief Intellectual Property Officer and Head of US Legal
• John de Kruif,
  Chief Technology Officer
• Sven Lundberg,
  President, Chief Executive Officer, Principal Financial Officer, Executive Director
• Anand Mehra,
  Non-Executive Independent Chairman of the Board
• Andrew Joe,
  Chief Medical Officer
• Paolo Pucci,
  Non-Executive Independent Director
• Victor Sandor,
  Non-Executive Independent Director
• Jillian Connell,
  Investor Relations & Corporate Communications
• Leonard Kanavy,
  Non-Executive Independent Director
• Gregory Perry,
  Independent Non-Executive Vice Chairman of the Board
• Mark Iwicki,
  Non-Executive Independent Director
• Shannon Campbell,
  Exec. VP & Chief Commercial Officer
• Dr. Cecile A.W. Geuijen Ph.D.,
  Chief Scientific Officer
• Anne Noordzij,
  Sec.
• Dr. Ellen Broug,
  Exec. Director of IP & Sec.
• Dr. Andrew Joe M.D.,
  Chief Medical Officer
• Alexander Berthold Hendrik Bakker Ph.D.,
  Chief Devel. Officer & Sr. VP
• Cornelis Adriaan de Kruif Ph.D.,
  CTO & Sr. VP
• Dr. Hennie Hoogenboom,
  Co-Founder and Scientific Advisor
• Partners L P/Ilbiotechnolog...,
  
• Lex Bakker,
  SVP, Chief Development Officer
• Mark Throsby,
  EVP & Chief Scientific Officer
• Partners L P/Ilbiotechnolog...,
  
• Corp Incyte,
  10% owner
• Cecile A W Geuijen,
  SVP & Chief Scientific Officer
• Jason Haddock,
  
• Maxine Gowen,
  
• Len Kanavy,
  
• Harry Shuman,
  VP Controller, PAO
• Fabian Zohren,
  Chief Medical Officer